Genzyme Oncology · Cambridge, MA United States
| 55 Cambridge Pkwy. | Phone: 617-761-8777 |
| Cambridge, MA | Fax: 617-761-8918 |
| 02142 | |
| United States | 
Map This Company |
Genzyme Oncology Rankings
Company Description
Genzyme Oncology is aiming for the jet set of the cancer therapeutics market. The company develops, manufactures, and markets traditional and gene-based cancer therapies. Its technology approaches include anti-angiogenesis, which halts the growth of blood vessels in tumors, and a program attacking cancer at the cellular level. Marketed products include Campath, for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and Clolar, which is used in the treatment of relapsed acute lymphoblastic leukemia (ALL) in children. Genzyme Oncology also develops therapeutics for hematology and immune system disorders. The company is a division of
Genzyme Oncology Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Business Segment |
|---|---|
| Fiscal Year-End | December |
Executives
7 executives listed for Genzyme Oncology's Cambridge, MA location.
| President and CEO | Henri Termeer | |
|---|---|---|
| SVP, Research and Development | Katherine Klinger | |
| SVP and Product General Manager | Terry Murdock |